v3.26.1
Stock-Based Compensation (Details Narrative) - USD ($)
$ / shares in Thousands, $ in Millions
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2025
May 15, 2018
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Unrecognized compensation cost $ 0.4      
Cost recognized period 1 year 2 months 12 days      
Weighted average grant date fair value per share $ 3,740      
Equity Stock Awards [Member] | Granted Under Two Thousand Eighteen Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Common stock, reserved for future issuance     264,665  
Equity Stock Awards [Member] | Granted Under Two Thousand Eighteen Plan And Prior Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Common stock, reserved for future issuance 339      
Stock Options and Restricted Stock Awards [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Share based compensation $ 0.6 $ 0.2    
Stock Options and Restricted Stock Awards [Member] | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Share based compensation 0.4 0.2    
Stock Options and Restricted Stock Awards [Member] | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Share based compensation $ 0.2 $ 0.1    
2018 Stock Incentive Plan [Member]        
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]        
Number of shares authorized       12,000
Stock options, strike price description Options are generally granted with strike prices equal to the fair market value of a share of Imunon common stock on the date of grant. Incentive stock options may be granted to purchase shares of common stock at a price not less than 100% of the fair market value of the underlying shares on the date of grant, provided that the exercise price of any incentive stock option granted to an eligible employee owning more than 10% of the outstanding stock of Imunon must be at least 110% of such fair market value on the date of grant. Only officers and key employees may receive incentive stock options.